Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 34
Filtrar
1.
J Laparoendosc Adv Surg Tech A ; 34(9): 814-821, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-38808528

RESUMO

Background: Duodenal stump fistula represents an infrequent but serious complication after laparoscopic radical gastrectomy with Billroth II or Roux-en-Y reconstruction for gastric cancer. The present study was designed to evaluate the effectiveness of laparoscopic double half purse-string sutures plus "8" pattern of stitching for reinforcement of duodenal stump. Methods: The data of patients undergoing laparoscopic radical gastrectomy with Billroth II or Roux-en-Y reconstruction were retrospectively analyzed between August 2022 and June 2023. According to the different reinforcement methods of duodenal stump, included patients were subdivided into three groups as follows: Group A, duodenal stump was treated with double half purse-string sutures plus "8" pattern of stitching; Group B, duodenal stump was reinforced by continuous suture using a barbed suture; and Group C, duodenal stump without any additional processing. The incidences of duodenal stump fistula between three groups were documented and compared. Moreover, the independent risk factors associated with duodenal stump fistula were analyzed using the logistic regression analysis. Results: No postoperative duodenal stump fistula occurred in Group A, which was significantly different from Group B and Group C (P = .007). In the multivariate analysis, age (odds ratio [OR], 1.191; 95% confidence interval [CI], 1.088-1.303), body mass index (OR, 0.824; 95% CI, 0.727-0.935), and American Society of Anesthesiologists score (OR, 4.495; 95% CI, 1.264-15.992) were the risk factors for duodenal stump fistula. Conclusion: Double half purse-string sutures plus "8" pattern of suture can be conducted in a relatively short operation period and could prevent the incidence of duodenal stump fistula to some extent.


Assuntos
Gastrectomia , Fístula Intestinal , Laparoscopia , Complicações Pós-Operatórias , Técnicas de Sutura , Humanos , Feminino , Masculino , Gastrectomia/efeitos adversos , Gastrectomia/métodos , Laparoscopia/métodos , Laparoscopia/efeitos adversos , Pessoa de Meia-Idade , Estudos Retrospectivos , Complicações Pós-Operatórias/prevenção & controle , Complicações Pós-Operatórias/etiologia , Fístula Intestinal/etiologia , Fístula Intestinal/prevenção & controle , Fístula Intestinal/cirurgia , Idoso , Neoplasias Gástricas/cirurgia , Duodenopatias/cirurgia , Duodenopatias/etiologia , Duodenopatias/prevenção & controle , Fatores de Risco , Gastroenterostomia/métodos
2.
Gastric Cancer ; 22(5): 1053-1059, 2019 09.
Artigo em Inglês | MEDLINE | ID: mdl-30852781

RESUMO

BACKGROUND: Although duodenal stump leakage (DSL) is a relatively rare complication after gastrectomy with Roux-en-Y (R-Y) reconstruction, it is difficult to treat and can be fatal. We investigated the impact of duodenal stump reinforcement on DSL after laparoscopic gastrectomy with R-Y reconstruction for gastric cancer. METHODS: This retrospective study of 965 patients with gastric cancer who underwent laparoscopic distal or total gastrectomy (LDG or LTG) with R-Y reconstruction compared surgical outcomes between two groups, the duodenal stump reinforcement group (reinforcement group) (n = 895) and that without duodenal stump reinforcement (non-reinforcement group) (n = 70). RESULTS: Mean operative duration was significantly longer in the reinforcement than in the non-reinforcement group (LDG; 291 min versus 258 min, p < 0.001, LTG; 325 min versus 285 min, p < 0.001). DSL occurred less frequently in the reinforcement than in the non-reinforcement group (0.67% vs. 5.71%, p < 0.001). Furthermore, non-reinforcement was an independent risk factor for DSL in multiple logistic regression analysis with adjustment for potential confounding factors. Patients with DSL in the non-reinforcement group all required re-operation, while all but one patient with DSL in the reinforcement group recovered with conservative management. CONCLUSIONS: Duodenal stump reinforcement in laparoscopic gastrectomy with R-Y reconstruction may reduce the risk of DSL development and minimize its severity.


Assuntos
Anastomose em-Y de Roux/efeitos adversos , Duodenopatias/prevenção & controle , Duodeno/cirurgia , Gastrectomia/efeitos adversos , Laparoscopia/efeitos adversos , Excisão de Linfonodo/efeitos adversos , Procedimentos de Cirurgia Plástica/efeitos adversos , Neoplasias Gástricas/tratamento farmacológico , Adulto , Idoso , Idoso de 80 Anos ou mais , Duodenopatias/epidemiologia , Duodenopatias/etiologia , Feminino , Seguimentos , Humanos , Incidência , Japão/epidemiologia , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Retrospectivos , Neoplasias Gástricas/patologia
3.
Zhonghua Wei Chang Wai Ke Za Zhi ; 20(3): 266-269, 2017 Mar 25.
Artigo em Chinês | MEDLINE | ID: mdl-28338158

RESUMO

Duodenal injury is a serious abdominal organ injury. Duodenal fistula is one of the most serious complications in gastrointestinal surgery, which is concerned for its critical status, difficulty in treatment and high mortality. Thoracic and abdominal compound closed injury and a small part of open injury are common causes of duodenal injury. Iatrogenic or traumatic injury, malnutrition, cancer, tuberculosis, Crohn's disease etc. are common causes of duodenal fistula, however, there has been still lacking of ideal diagnosis and treatment by now. The primary treatment strategy of duodenal fistula is to determine the cause of disease and its key point is prevention, including perioperative parenteral and enteral nutrition support, improvement of hypoproteinemia actively, avoidance of stump ischemia by excessive separate duodenum intraoperatively, performance of appropriate duodenum stump suture to ensure the stump blood supply, and avoidance of postoperative input loop obstruction, postoperative stump bleeding or hematoma etc. Once duodenal fistula occurs, a simple and reasonable operation can be selected and performed after fluid prohibition, parenteral and enteral nutrition, acid suppression, enzyme inhibition, anti-infective treatment and maintaining water salt electrolyte and acid-base balance. Double tube method, duodenal decompression and peritoneal drainage can reduce duodenal fistula-related complications, and then reduce the mortality, which can save the lives of patients.


Assuntos
Procedimentos Cirúrgicos do Sistema Digestório/efeitos adversos , Procedimentos Cirúrgicos do Sistema Digestório/métodos , Duodenopatias/prevenção & controle , Duodenopatias/terapia , Duodeno/lesões , Duodeno/cirurgia , Fístula Intestinal/prevenção & controle , Fístula Intestinal/terapia , Traumatismos Abdominais/complicações , Anti-Infecciosos/uso terapêutico , Descompressão Cirúrgica , Drenagem , Duodenopatias/diagnóstico , Duodenopatias/etiologia , Duodeno/irrigação sanguínea , Nutrição Enteral , Humanos , Hipoproteinemia/terapia , Fístula Intestinal/diagnóstico , Fístula Intestinal/etiologia , Isquemia/prevenção & controle , Apoio Nutricional , Nutrição Parenteral , Complicações Pós-Operatórias/prevenção & controle , Complicações Pós-Operatórias/terapia , Técnicas de Sutura , Traumatismos Torácicos/complicações
6.
Khirurgiia (Mosk) ; (6): 43-7, 2014.
Artigo em Russo | MEDLINE | ID: mdl-25042190

RESUMO

It was analyzed the examination and treatment results of 100 patients who underwent resection of stomach by Billroth-I in case of peptic ulcer. Chronic disorders of duodenal patency were diagnosed in 86% of patients. The main role of chronic disorders of duodenal patency in postgastrectomy syndromes development was proved. There were a combination of reflux gastritis with dumping syndrome in 66.3% of patients, a combination of reflux gastritis with recurrent ulcer in 8.1% of patients. Correction of chronic disorders of duodenal patency is necessary stage in conservative and surgical treatment of postgastrectomy syndromes.


Assuntos
Duodenopatias/etiologia , Gastrectomia , Gastroenterostomia , Úlcera Péptica , Síndromes Pós-Gastrectomia , Úlcera Gástrica , Adulto , Doença Crônica , Duodenopatias/fisiopatologia , Duodenopatias/prevenção & controle , Duodeno/fisiopatologia , Duodeno/cirurgia , Endoscopia Gastrointestinal/métodos , Feminino , Gastrectomia/efeitos adversos , Gastrectomia/métodos , Gastroenterostomia/efeitos adversos , Gastroenterostomia/métodos , Motilidade Gastrointestinal , Humanos , Masculino , Pessoa de Meia-Idade , Úlcera Péptica/diagnóstico , Úlcera Péptica/fisiopatologia , Úlcera Péptica/cirurgia , Síndromes Pós-Gastrectomia/diagnóstico , Síndromes Pós-Gastrectomia/fisiopatologia , Síndromes Pós-Gastrectomia/prevenção & controle , Recidiva , Úlcera Gástrica/diagnóstico , Úlcera Gástrica/fisiopatologia , Úlcera Gástrica/cirurgia , Resultado do Tratamento
7.
Gastrointest Endosc Clin N Am ; 24(2): 235-44, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24679234

RESUMO

Duodenal endoscopic submucosal dissection (ESD) is technically difficult due to the unique anatomic features. The risks include intraprocedural complications, delayed bleeding, and perforation. A small-caliber-tip transparent hood is useful. Mechanical stretching of the submucosal tissue allows safe dissection and effective prevention of bleeding with minimum muscle injury under direct visualization of the submucosal tissue and blood vessels. A short double-balloon endoscope is useful to stabilize control of the endoscope tip in distal duodenal ESD. Selection of ESD in the duodenum should be made cautiously considering both benefits and risks of the procedure.


Assuntos
Adenocarcinoma/cirurgia , Perda Sanguínea Cirúrgica/prevenção & controle , Duodenopatias/prevenção & controle , Neoplasias Duodenais/cirurgia , Endoscopia Gastrointestinal/métodos , Hemorragia Gastrointestinal/prevenção & controle , Mucosa Intestinal/cirurgia , Perfuração Intestinal/prevenção & controle , Hemorragia Pós-Operatória/prevenção & controle , Dissecação/métodos , Humanos , Seleção de Pacientes
8.
World J Gastroenterol ; 19(34): 5671-7, 2013 Sep 14.
Artigo em Inglês | MEDLINE | ID: mdl-24039360

RESUMO

AIM: To evaluate if 3 mo oral supplementation with Eviendep® was able to reduce the number of duodenal polyps in familial adenomatous polyposis (FAP) patients with ileal pouch-anal anastomosis (IPAA). METHODS: Eleven FAP patients with IPAA and duodenal polyps were enrolled. They underwent upper gastrointestinal (GI) endoscopy at the baseline and after 3 mo of treatment. Each patient received 5 mg Eviendep twice a day, at breakfast and dinner time, for 3 mo. Two endoscopists evaluated in a blinded manner the number and size of duodenal polyps. Upper GI endoscopies with biopsies were performed at the baseline (T0) with the assessment of the Spigelman score. Polyps > 10 mm were removed during endoscopy and at the end of the procedure a new Spigelman score was determined (T1). The procedure was repeated 3 mo after the baseline (T2). Four photograms were examined for each patient, at T1 and T2. The examined area was divided into 3 segments: duodenal bulb, second and third portion duodenum. Biopsy specimens were taken from all polyps > 10 mm and from all suspicious ones, defined by the presence of a central depression, irregular surface, or irregular vascular pattern. Histology was classified according to the updated Vienna criteria. RESULTS: At baseline the mean number of duodenal detected polyps was 27.7 and mean sizes were 15.8 mm; the mean Spigelman score was 7.1. After polypectomy the mean number of duodenal detected polyps was 25.7 and mean sizes were 7.6 mm; the mean Spigelman score was 6.4. After 3 mo of Eviendep bid, all patients showed a reduction of number and size of duodenal polyps. The mean number of duodenal polyps was 8 (P = 0.021) and mean size was 4.4 mm; the mean Spigelman score was 6.6. Interrater agreement was measured. Lesions > 1 cm found a very good degree of concordance (kappa 0.851) and a good concordance was as well encountered for smaller lesions (kappa 0.641). CONCLUSION: Our study demonstrated that short-term (90 d) supplementation with Eviendep® in FAP patients with IPAA and with recurrent adenomas in the duodenal mucosa, resulted effective in reducing polyps number of 32% and size of 51%.


Assuntos
Polipose Adenomatosa do Colo/tratamento farmacológico , Duodenopatias/prevenção & controle , Pólipos Intestinais/prevenção & controle , Fitoestrógenos/uso terapêutico , Fitoterapia , Polipose Adenomatosa do Colo/dietoterapia , Polipose Adenomatosa do Colo/cirurgia , Adolescente , Adulto , Anastomose Cirúrgica , Bolsas Cólicas , Fibras na Dieta/uso terapêutico , Feminino , Humanos , Masculino , Extratos Vegetais/uso terapêutico , Adulto Jovem
9.
JSLS ; 17(2): 306-11, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23925026

RESUMO

BACKGROUND AND OBJECTIVES: Bowel distention from luminal gas insufflation reduces the peritoneal operative domain during natural orifice transluminal endoscopic surgery (NOTES) procedures, increases the risk for iatrogenic injury, and leads to postoperative patient discomfort. METHODS: A prototype duodenal occlusion device was placed in the duodenum before NOTES in 28 female pigs. The occlusion balloon was inflated and left in place during the procedure, and small bowel distension was subjectively graded. One animal had no balloon occlusion, and 4 animals had a noncompliant balloon placed. RESULTS: The balloon maintained its position and duodenal occlusion in 22 animals (79%) in which the bowel distention was rated as none (15), minor (4), moderate (3), or severe (0). The intestinal occlusion catheter failed in 6 animals (21%) because of balloon leak (5) or back-migration into the stomach (1), with distention rated as severe in 5 of these 6 cases. CONCLUSION: The intestinal occlusion catheter that maintains duodenal occlusion significantly improves the intraabdominal working domain with enhanced visualization of the viscera during the NOTES procedure while requiring minimal time and expense.


Assuntos
Oclusão com Balão/instrumentação , Perfuração Intestinal/prevenção & controle , Cirurgia Endoscópica por Orifício Natural/instrumentação , Animais , Duodenopatias/prevenção & controle , Desenho de Equipamento , Feminino , Insuflação , Cirurgia Endoscópica por Orifício Natural/efeitos adversos , Suínos
10.
Gig Sanit ; (6): 85-7, 2012.
Artigo em Russo | MEDLINE | ID: mdl-23458008

RESUMO

Assessment of health status of the population - the most important issue in preventive medicine. The objective of this work - to determine the possibility of nonendoscopic screening for gastroduodenal pathology, by the example of atrophic gastritis, in mass medical examinations of working residents in Moscow. Minimally invasive diagnostic test system GastroPanel ("Biohit", Finland) has been used. It allows with the ELISA method to determine both serum indicators of the function of the stomach -pepsinogen 1, gastrin 17 and the presence of H. pylori infection. 758 persons have been examined. The performed study confirms the possibility with the use of a set of mentioned indicators to identify individuals suspected for the presence of gastroduodenal disorders, especially atrophic gastritis, recognized as a precancerous condition. The use in preventive medicine complex diagnostic system, firstly, will make assessment of the health of the population more correct, increase the effectiveness of preventive measures and quality of life, and secondly, will contribute to the diagnosis of diseases of the stomach and duodenum in the early stages.


Assuntos
Duodenopatias/diagnóstico , Gastrite Atrófica/diagnóstico , Infecções por Helicobacter/diagnóstico , Programas de Rastreamento/organização & administração , Prevenção Primária/organização & administração , Saúde Pública/métodos , Adolescente , Adulto , Idoso , Duodenopatias/sangue , Duodenopatias/microbiologia , Duodenopatias/prevenção & controle , Ensaio de Imunoadsorção Enzimática , Feminino , Gastrinas/sangue , Gastrite Atrófica/sangue , Gastrite Atrófica/microbiologia , Gastrite Atrófica/prevenção & controle , Infecções por Helicobacter/sangue , Infecções por Helicobacter/microbiologia , Infecções por Helicobacter/prevenção & controle , Helicobacter pylori/isolamento & purificação , Humanos , Masculino , Programas de Rastreamento/métodos , Pessoa de Meia-Idade , Moscou , Pepsinogênio A/sangue , Prevenção Primária/métodos , Adulto Jovem
11.
J Gastroenterol Hepatol ; 24(7): 1169-78, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19682191

RESUMO

Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly prescribed drugs worldwide, which attests to their efficacy as analgesic, antipyretic and anti-inflammatory agents as well as anticancer drugs. However, NSAID use also carries a risk of major gastroduodenal events, including symptomatic ulcers and their serious complications that can lead to fatal outcomes. The development of "coxibs" (selective cyclooxygenase-2 [COX-2] inhibitors) offered similar efficacy with reduced toxicity, but this promise of gastroduodenal safety has only partially been fulfilled, and is now dented with associated risks of cardiovascular or intestinal complications. Recent advances in basic science and biotechnology have given insights into molecular mechanisms of NSAID-induced gastroduodenal damage beyond COX-2 inhibition. The emergence of newer kinds of NSAIDs should alleviate gastroduodenal toxicity without compromising innate drug efficacy. In this review, novel strategies for avoiding NSAID-associated gastroduodenal damage will be described.


Assuntos
Anti-Inflamatórios não Esteroides/efeitos adversos , Desenho de Fármacos , Duodenopatias/prevenção & controle , Gastropatias/prevenção & controle , Animais , Anti-Inflamatórios não Esteroides/química , Qualidade de Produtos para o Consumidor , Inibidores de Ciclo-Oxigenase 2/efeitos adversos , Duodenopatias/induzido quimicamente , Duodenopatias/patologia , Humanos , Medição de Risco , Gastropatias/induzido quimicamente , Gastropatias/patologia , Relação Estrutura-Atividade
12.
Endocrinology ; 149(9): 4554-66, 2008 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-18499763

RESUMO

Because human duodenal mucosal bicarbonate secretion (DMBS) protects duodenum against acid-peptic injury, we hypothesize that estrogen stimulates DMBS, thereby attributing to the clinically observed lower incidence of duodenal ulcer in premenopausal women than the age-matched men. We found that basal and acid-stimulated DMBS responses were 1.5 and 2.4-fold higher in female than male mice in vivo, respectively. Acid-stimulated DMBS in both genders was abolished by ICI 182,780 and tamoxifen. Estradiol-17beta (E2) and the selective estrogen receptor (ER) agonists of ERalpha [1,3,5-Tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole] and ERbeta [2,3-bis(4-hydroxyphenyl) propionitrile], but not progesterone, rapidly stimulated ER-dependent murine DMBS in vivo. E2 dose dependently stimulated murine DMBS, which was attenuated by a Cl(-)/HCO3(-) anion exchanger inhibitor 4,4'-didsothio- cyanostilbene-2, 2'-disulfonic acid, removal of extracellular Cl(-), and in cystic fibrosis transmembrane conductance regulator knockout female mice. E2 stimulated murine DMBS in vitro in both genders with significantly greater response in female than male mice (female to male ratio = 4.3). ERalpha and ERbeta mRNAs and proteins were detected in murine duodenal epithelium of both genders; however, neither ERalpha nor ERbeta mRNA and protein expression levels differed according to gender. E2 rapidly mobilized intracellular calcium in a duodenal epithelial SCBN cell line that expresses ERalpha and ERbeta, whereas BAPTA-AM abolished E2-stimulated murine DMBS. Thus, our data show that E2 stimulates DMBS via ER dependent mechanisms linked to intracellular calcium, cystic fibrosis transmembrane conductance regulator, and Cl(-)/HCO3(-) anion exchanger. Gender-associated differences in basal, acid- and E2-stimulated DMBS may have offered a reasonable explanation for the clinically observed lower incidence of duodenal ulcer in premenopausal women than age-matched men.


Assuntos
Bicarbonatos/metabolismo , Citoproteção/efeitos dos fármacos , Duodenopatias/prevenção & controle , Estradiol/farmacologia , Ácido Gástrico/fisiologia , Mucosa Intestinal/efeitos dos fármacos , Caracteres Sexuais , Animais , Células Cultivadas , Citoproteção/fisiologia , Cães , Duodenopatias/etiologia , Duodenopatias/metabolismo , Estradiol/análogos & derivados , Estradiol/metabolismo , Estradiol/uso terapêutico , Antagonistas de Estrogênios/metabolismo , Antagonistas de Estrogênios/farmacologia , Feminino , Fulvestranto , Mucosa Intestinal/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Receptores de Estrogênio/metabolismo , Receptores de Estrogênio/fisiologia , Tamoxifeno/metabolismo , Tamoxifeno/farmacologia
14.
J Gastrointest Surg ; 9(7): 915-21, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-16137584

RESUMO

The study goal was to determine the technical feasibility and outcomes associated with pancreaticoduodenectomy for periampullary malignancies with near (>80%) or complete (100%) superior mesenteric venous (SMV) obstruction. A retrospective examination of 11 patients with high-grade or complete SMV obstruction who underwent pancreaticoduodenectomy at five academic medical centers is reviewed. Pancreaticoduodenectomy for locally advanced periampullary malignancies causing high-grade or complete SMV obstruction is technically feasible. Operative approaches and outcomes are presented. One 30-day death was observed. Median survival of the cohort is 18 months. Survivals exceeding 2 years post-resection have been observed. In a number of cases, significant palliation of pain and of biliary and duodenal obstruction were achieved. Based on this initial series, pancreaticoduodenectomy in the presence of near or total SMV obstruction is feasible, may result in an R0 resection, and may be beneficial in select patients with a periampullary malignancy. We suggest such an approach be considered particularly following completion of neoadjuvant therapy without systemic progression. Further studies and more long-term follow-up at high-volume centers are required, however, to better determine the indications and potential benefit of such an undertaking.


Assuntos
Oclusão Vascular Mesentérica/complicações , Veias Mesentéricas/patologia , Neoplasias Pancreáticas/cirurgia , Pancreaticoduodenectomia/métodos , Idoso , Causas de Morte , Colestase/prevenção & controle , Estudos de Coortes , Duodenopatias/prevenção & controle , Estudos de Viabilidade , Seguimentos , Hemorragia Gastrointestinal/prevenção & controle , Humanos , Obstrução Intestinal/prevenção & controle , Pessoa de Meia-Idade , Terapia Neoadjuvante , Dor/prevenção & controle , Cuidados Paliativos , Pancreaticoduodenectomia/efeitos adversos , Complicações Pós-Operatórias , Estudos Retrospectivos , Taxa de Sobrevida , Resultado do Tratamento
16.
Gut ; 53(3): 381-6, 2004 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-14960520

RESUMO

BACKGROUND: The prevalence of duodenal carcinoma is much higher in familial adenomatous polyposis (FAP) than in the background population, and duodenal adenomatosis is found in most polyposis patients. AIMS: To describe the long term natural history of duodenal adenomatosis in FAP and evaluate if cancer prophylactic surveillance of the duodenum is indicated. METHODS: A prospective five nation study was carried out in the Nordic countries and the Netherlands. PATIENTS: A total of 368 patients were examined by gastroduodenoscopy at two year intervals during the period 1990-2001. RESULTS: At the first endoscopy, 238 (65%) patients had duodenal adenomas at a median age of 38 years. Median follow up was 7.6 years. The cumulative incidence of adenomatosis at age 70 years was 90% (95% confidence interval (CI) 79-100%), and of Spigelman stage IV 52% (95% CI 28-76%). The probability of an advanced Spigelman score increased during the study period (p<0.0001) due to an increasing number and size of adenomas. Two patients had asymptomatic duodenal carcinoma at their first endoscopy while four developed carcinoma during the study at a median age of 52 years (range 26-58). The cumulative incidence rate of cancer was 4.5% at age 57 years (95% CI 0.1-8.9%) and the risk was higher in patients with Spigelman stage IV at their first endoscopy than in those with stages 0-III (p<0.01). CONCLUSIONS: The natural course of duodenal adenomatosis has now been described in detail. The high incidence and increasing severity of duodenal adenomatosis with age justifies prophylactic examination, and a programme is presented for upper gastrointestinal endoscopic surveillance.


Assuntos
Polipose Adenomatosa do Colo/complicações , Duodenopatias/etiologia , Polipose Adenomatosa do Colo/patologia , Adolescente , Adulto , Idoso , Criança , Progressão da Doença , Duodenopatias/patologia , Duodenopatias/prevenção & controle , Neoplasias Duodenais/etiologia , Neoplasias Duodenais/patologia , Neoplasias Duodenais/prevenção & controle , Feminino , Seguimentos , Humanos , Polipose Intestinal/patologia , Polipose Intestinal/prevenção & controle , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Vigilância da População/métodos , Estudos Prospectivos
17.
Kyobu Geka ; 45(6): 495-7, 1992 Jun.
Artigo em Japonês | MEDLINE | ID: mdl-1602675

RESUMO

The efficacy of cimetidine administration after the open heart surgery was studied using the cimetidine concentration examination in the twenty five consecutive cases. Cimetidine was administered intravenously. The cases were divided into five groups for the infusion period. There was no case which developed the gastro-duodenal bleeding after the surgery. The concentration of cimetidine has showed more than 0.5 microgram/ml in each group. It was concluded that the administration of 800 mg cimetidine infused more than three hours, repeated every twelve hours was the possible treatment for the prevention of the gastro-duodenal bleeding after the open heart surgery.


Assuntos
Cimetidina/uso terapêutico , Duodenopatias/prevenção & controle , Hemorragia Gastrointestinal/prevenção & controle , Cardiopatias/cirurgia , Complicações Pós-Operatórias/prevenção & controle , Gastropatias/prevenção & controle , Adolescente , Adulto , Criança , Cimetidina/administração & dosagem , Esquema de Medicação , Avaliação de Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
18.
Am J Gastroenterol ; 86(12): 1743-8, 1991 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-1962619

RESUMO

Ninety-one normal, healthy volunteers participated in a single-center, double-blind, placebo-controlled, randomized, parallel group study: 1) to compare the prostaglandin E1 analog, misoprostol, given at a dose of 200 micrograms bid, with the recommended dose of 200 micrograms qid in protecting the gastroduodenal mucosa against injury due to anti-inflammatory doses of aspirin (3900 mg/day); and 2) to determine whether the reduced dose was associated with a lesser incidence of gastrointestinal (GI) side effects, particularly diarrhea. All subjects received 975 mg of aspirin qid with meals and at bedtime. They were concurrently administered either misoprostol 200 micrograms qid, misoprostol 200 micrograms bid and placebo bid, or placebo qid. All subjects were endoscopically normal at the onset of the study and were re-endoscoped on the morning of the 7th day of therapy, 2 h after the morning dose of medications. Gastric and duodenal mucosa were assessed separately on a 0-7 scale which gave a greater weight to erosions than to hemorrhages. GI symptoms, especially bowel habits, were assessed by means of diary cards. Subjects in both misoprostol groups had significantly less gastric and duodenal mucosal injury than subjects who received placebo (p less than 0.007 for each pairwise comparison). There was no statistically significant difference between the two misoprostol groups (p less than 0.093). Subjects in the misoprostol 200 micrograms qid group had significantly more loose and watery bowel movements than the subjects in the misoprostol 200 micrograms bid group (p less than 0.013), whereas there were no significant differences in bowel habits between the misoprostol 200 micrograms bid and placebo groups (p less than 0.122). More subjects in the misoprostol 200 micrograms qid group reported abdominal pain, loose stools, watery stools, flatulence, dyspepsia, and nausea than in the misoprostol 200 micrograms bid and placebo groups. In conclusion, the adverse events in the misoprostol 200 micrograms bid group were not significantly different from those in the placebo group, and were significantly better than in the misoprostol 200 micrograms qid group. The lower dose retained mucosal protective activity that was statistically indistinguishable from that of misoprostol 200 micrograms qid.


Assuntos
Aspirina/efeitos adversos , Duodenopatias/prevenção & controle , Misoprostol/administração & dosagem , Gastropatias/prevenção & controle , Adulto , Diarreia/induzido quimicamente , Método Duplo-Cego , Duodenopatias/induzido quimicamente , Duodenopatias/patologia , Duodenoscopia , Feminino , Mucosa Gástrica/patologia , Gastroscopia , Humanos , Mucosa Intestinal/patologia , Masculino , Pessoa de Meia-Idade , Misoprostol/efeitos adversos , Gastropatias/induzido quimicamente , Gastropatias/patologia
19.
Eur J Clin Invest ; 21(2): 230-7, 1991 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-1905637

RESUMO

Eight healthy volunteers were studied before and after 3 weeks of dietary supplementation with fish oil (10.5 g day-1, 18% (1.9 g) eicosapentaenoic acid). Duodenal mucosal lesions were induced by instillation of 40 ml ethanol (40%). Mean endoscopic lesion score was lower after fish oil treatment (1.62 +/- 0.32; mean +/- SEM) than before (3.25 +/- 0.31; P less than 0.01). Histologic lesion score fell from 22.75 +/- 1.98 before treatment to 13.50 +/- 1.51 after fish oil (P less than 0.01). Basal and pentagastrin-stimulated gastric acid output remained unaffected. Release of prostaglandin E2, 6-keto-prostaglandin F1 alpha, and thromboxane B2 from biopsy specimens of the duodenal mucosa in vitro was not significantly altered after fish oil ingestion. In the same in vitro system calcium ionophore A23187-induced release of total leukotriene C (LTC) increased from 10.6 +/- 1.5 ng g-1 mucosa 20 min before treatment to 30.4 +/- 3.2 ng after fish oil. High pressure liquid chromatography analysis showed that this increase was partly due to formation of LTC5 as after fish oil 28% of total LTC were identified as LTC5 whereas 72% were LTC4. We conclude that in humans fish oil reduces ethanol-induced damage of the duodenal mucosa without inhibiting gastric acid secretion or stimulating prostaglandin formation. It remains to be clarified if the changes in leukotriene formation are relevant for the mucosaprotective fish oil effect.


Assuntos
Duodenopatias/prevenção & controle , Etanol/antagonistas & inibidores , Óleos de Peixe/uso terapêutico , Mucosa Intestinal/efeitos dos fármacos , 6-Cetoprostaglandina F1 alfa/metabolismo , Adulto , Biópsia , Cromatografia Líquida de Alta Pressão/métodos , Dinoprostona/metabolismo , Duodenopatias/induzido quimicamente , Duodenopatias/patologia , Duodenoscopia , Feminino , Ácido Gástrico/metabolismo , Humanos , Técnicas In Vitro , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patologia , Masculino , SRS-A/metabolismo , Tromboxano B2/metabolismo
20.
Am Surg ; 57(1): 24-8, 1991 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-1724593

RESUMO

This review was undertaken to determine whether there are specific factors which predict the development of gastric outlet obstruction (GOO) in patients with pancreatic carcinoma. One hundred forty-two patients with biopsy proven pancreatic carcinoma had palliative operations of whom 74 had gastric bypass (GB). Of the 68 who did not, four died after biliary bypass. The 64 patients who remained at risk for GOO are the subject of this report. Seven of those patients developed GOO in the postoperative period and were compared with the 57 who did not. No significant difference was found between the two groups when they were compared on the basis of 20 historic, laboratory, and operative finding criteria. These data indicate that accurate prediction of subsequent GOO is not possible based on available objective data. Because GB creation does not increase operative blood loss, operative time, postoperative stay, or postoperative morbidity, and because prediction of need is difficult, prophylactic GB should be applied very liberally.


Assuntos
Adenocarcinoma/cirurgia , Derivação Gástrica , Cuidados Paliativos , Neoplasias Pancreáticas/cirurgia , Coledocostomia , Duodenopatias/etiologia , Duodenopatias/prevenção & controle , Feminino , Humanos , Obstrução Intestinal/etiologia , Obstrução Intestinal/prevenção & controle , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de Risco , Volvo Gástrico/etiologia , Volvo Gástrico/prevenção & controle , Taxa de Sobrevida
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA